Bump for Baltimore biotech taking on age-related frailty

1 August 2023

Age-related and autoimmune disease specialist MyMD Pharmaceuticals (Nasdaq: MYMD) has announced positive Phase II data for its oral TNF-α inhibitor, MYMD-1.

The Baltimore, USA-based company saw its shares jump by a third on Monday, following the announcement that the novel sarcopenia medicine performed well in the trial, which met both primary endpoints.

MyMD is testing the drug for the treatment of chronic inflammation associated with sarcopenia, also known as age-related frailty, an indication for which there are no approved products.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK